Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Decitabine for High-Risk Sickle Cell Disease

This study has been completed.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ) Identifier:
First received: June 16, 2011
Last updated: August 31, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2016
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)